# Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

> **NCT06472245** · PHASE3 · RECRUITING · sponsor: **OSE Immunotherapeutics** · enrollment: 363 (estimated)

## Conditions studied

- Patients With Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** OSE2101
- **DRUG:** Docetaxel
- **DEVICE:** NGS HLAA2 assay

## Key facts

- **NCT ID:** NCT06472245
- **Lead sponsor:** OSE Immunotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-03
- **Primary completion:** 2027-12-15
- **Final completion:** 2028-12-15
- **Target enrollment:** 363 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06472245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06472245, "Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06472245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*